New therapeutic targets for osteoporosis: Beyond denosumab

Maturitas

Volumn 73, Issue 3, 2012, Pages 269-272

  Lim, Vivien ^a   Clarke, Bart L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti dickkopf antibody; Anti sclerostin antibody; Cathepsin K inhibitors; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BETA CATENIN; CALCITONIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; DENOSUMAB; DICKKOPF 1 PROTEIN; MONOCLONAL ANTIBODY; ODANACATIB; ONO 5334; PARATHYROID GLAND HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PTH 1-84; RALOXIFENE; RH 2 18; ROMOSOZUMAB; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

BONE DENSITY; DRUG APPROVAL; FRACTURE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INTRACELLULAR SIGNALING; MORPHEA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; WNT SIGNALING PATHWAY;

ANABOLIC AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CATHEPSIN K; FRACTURES, BONE; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE; TERIPARATIDE;

EID: 84867336111     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.08.002     Document Type: Review

References (27)

1. S. Boonen, E. Rosenberg, and F. Claessens Inhibition of cathepsin K for treatment of osteoporosis Curr Osteop Rep 10 2012 73 79
2. A.G. Costa, N.E. Costano, and B.C. Silva Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis Nat Rev Rheumatol 7 2011 447 456
3. J.A. Eisman, H.G. Bone, and D.J. Hosking Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect J Bone Miner Res 26 2011 242 251
4. H.G. Bone, M.R. McClung, and C. Roux Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density J Bone Miner Res 25 2010 937 947
5. S.A. Stoch, S. Zajic, and J. Stone Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clin Pharmacol Ther 86 2009 175 182
6. T. Cusick, C.M. Chen, and B.L. Pennypacker Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey J Bone Miner Res 27 2012 524 537
7. P.J. Masarachia, B.L. Pennypacker, and M. Pickarski Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys J Bone Miner Res 27 2012 509 523
8. S. Nagase, M. Ohyama, and Y. Hashimoto Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study J Clin Pharmacol. 52 2012 306 318
9. R. Eastell, S. Nagase, and M. Ohyama Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study J Bone Miner Res 26 2011 1303 1312
10. T.M. Rünger, S. Adami, and C.L. Benhamou Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib J Am Acad Dermatol 66 2012 e89 e96
11. R.M. Neer, C.D. Arnaud, and J.R. Zanchetta Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
12. D.M. Black, S.L. Greenspan, and K.E. Ensrud The effects of parathyroid hormone and alendronate alone or in combination for postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
13. D.M. Black, J.P. Bilezikian, and K.E. Ensrud One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 2005 555 565
14. V. Subbiah, V.S. Madsen, and A.K. Raymond Of mice and men: divergent risks of teriparatide-induced osteosarcoma Osteoporosis Int 21 2010 1041 1045
15. T. Nakamura, T. Sugimoto, and T. Nakano Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk J Clin Endocrinol Metab 2012 Epub date 6/23/2012
16. T. Ponnapakkam, R. Katikaneni, and H. Suda A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice Calcif Tiss Int 2012 [Epub date 7/19/2012]
17. T. Ponnapakkam, R. Katikaneni, and E. Miller Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice Calcif Tiss Int 88 2011 511 520
18. S.P. Hammerle, L. Mindeholm, and A. Launonen The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women Bone 50 2012 965 973
19. L.A. Fitzpatrick, C.E. Dabrowski, and G. Cicconetti The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density J Clin Endocrinol Metab 96 2011 2441 2449
20. S. Kimura, T. Nakagawa, and Y. Matsuo JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats Eur J Pharmacol 668 2011 331 336
21. G. Hattersley, J. Downall, and M. Shomali BA058, a novel hPTHrP analog, reverses bone loss and improves bone strength in ovariectomized rats Oral presentation 13-6, The Endocrine Society's 94th Annual Meeting and Expo, Houston, Texas, June 23-26 2012
22. V. Krishnan, H.U. Bryant, and O.A. Macdougald Regulation of bone mass by Wnt signaling J Clin Invest 116 2006 1202 1209
23. X. Li, M.S. Ominsky, and K.S. Warmington Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 24 2009 578 588
24. D. Padhi, G. Jang, and B. Stouch Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 26 2011 19 26
25. H. Glantschnig, K. Scott, and R. Hamptom A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody J Pharmacol Exp Ther 338 2011 568 578
26. M. Cicciu, A.S. Herford, and G. Juodzbalys Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw J Craniofacial Surg 23 2012 784 788
27. B. Skoglund, C. Forslund, and P. Aspenberg Simvastatin improves fracture healing in mice J Bone Miner Res 17 2002 2004 2008